| 151 |
21143106 | Long-acting insulin analogs: a review of "real-world" effectiveness in patients with type 2 diabetes. | 2011 Jan |
2 |
| 152 |
21338921 | Direct activation of Epac by sulfonylurea is isoform selective. | 2011 Feb 25 |
2 |
| 153 |
21410858 | Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*. | 2011 Aug |
1 |
| 154 |
21442682 | Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case-control study. | 2011 Apr |
1 |
| 155 |
21453253 | Adiponectin as a regulator of vascular redox state: therapeutic implications. | 2011 May |
1 |
| 156 |
21477042 | Glitazone-like action of glimepiride and glibenclamide in primary human adipocytes. | 2011 Sep |
2 |
| 157 |
21550959 | Concomitant oral antihyperglycemic agent use and associated treatment outcomes after initiation of insulin therapy. | 2011 Jul-Aug |
1 |
| 158 |
21872103 | Comment: "Quantitative insulin and C peptide levels among ED patients with sulfonylurea-induced hypoglycemia". | 2011 Sep |
1 |
| 159 |
21901702 | Interventions for latent autoimmune diabetes (LADA) in adults. | 2011 Sep 7 |
12 |
| 160 |
21959939 | [Pharmacogenetics of insulin secretagogue antidiabetics]. | 2011 Oct 9 |
2 |
| 161 |
22069291 | Pioglitazone may accelerate disease course of slowly progressive type 1 diabetes. | 2011 Nov |
1 |
| 162 |
24843477 | Genetics and pathophysiology of neonatal diabetes mellitus. | 2011 Jun 5 |
1 |
| 163 |
19656320 | Successful sulfonylurea treatment of an insulin-naïve neonate with diabetes mellitus due to a KCNJ11 mutation. | 2010 Jun |
1 |
| 164 |
20177722 | Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus. | 2010 Sep |
1 |
| 165 |
20205108 | Does cellular glucose transport respond to a controlled diet and sulfonylurea therapy in type 2 diabetes mellitus? | 2010 Jan-Feb |
1 |
| 166 |
20222815 | Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. | 2010 Mar |
1 |
| 167 |
20350924 | Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus. | 2010 Jul-Aug |
1 |
| 168 |
20361306 | Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide. | 2010 Mar |
1 |
| 169 |
20425680 | [Diabetes, insulin, insulin analogues, and cancer]. | 2010 May |
3 |
| 170 |
20540435 | [Low doses of sulphonyluria as a successful replacement for insulin therapy in a patient with neonatal diabetes due to a mutation of KCNJ11 gene encoding Kir6.2]. | 2010 Mar-Apr |
1 |
| 171 |
20804735 | Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion. | 2010 Sep 24 |
1 |
| 172 |
20887914 | Quantitative insulin and C-peptide levels among ED patients with sulfonylurea-induced hypoglycemia-a prospective case series. | 2010 Oct |
7 |
| 173 |
21426008 | Antidiabetic sulfonylureas modulate farnesoid X receptor activation and target gene transcription. | 2010 Apr |
1 |
| 174 |
22166651 | Appropriate insulin initiation dosage for insulin-naive type 2 diabetes outpatients receiving insulin monotherapy or in combination with metformin and/or pioglitazone. | 2010 Dec |
1 |
| 175 |
23226049 | The molecular mechanisms and pharmacotherapy of ATP-sensitive potassium channel gene mutations underlying neonatal diabetes. | 2010 |
2 |
| 176 |
24843406 | Sulfonylurea action re-revisited. | 2010 Apr 22 |
3 |
| 177 |
18548275 | Transition from insulin to sulfonylurea in a child with diabetes due to a mutation in KCNJ11 encoding Kir6.2--initial and long-term response to sulfonylurea therapy. | 2009 Mar |
1 |
| 178 |
18768334 | Cardiovascular prevention in type 2 diabetes mellitus patients: the role of oral glucose-lowering agents. | 2009 Nov-Dec |
1 |
| 179 |
19021632 | Mutations in the ABCC8 (SUR1 subunit of the K(ATP) channel) gene are associated with a variable clinical phenotype. | 2009 Sep |
2 |
| 180 |
19050053 | KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. | 2009 Feb |
2 |
| 181 |
19065048 | Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes. | 2009 Jan |
1 |
| 182 |
19175375 | Insulin therapy in type 2 diabetes: what is the evidence? | 2009 May |
2 |
| 183 |
19275673 | The endocannabinoid system: a promising target for the management of type 2 diabetes. | 2009 Feb |
1 |
| 184 |
19298459 | Free fatty acid kinetics during long-term treatment with pioglitazone added to sulfonylurea or metformin in Type 2 diabetes. | 2009 Apr |
1 |
| 185 |
19342262 | Mutations in the ABCC8 gene can cause autoantibody-negative insulin-dependent diabetes. | 2009 Jun |
1 |
| 186 |
19421967 | Balancing risk and benefit with oral hypoglycemic drugs. | 2009 Jun |
1 |
| 187 |
19692134 | Effect of sulfonylureas on switching to insulin therapy (twice-daily biphasic insulin aspart 30): comparison of twice-daily biphasic insulin aspart 30 with or without glimepiride in type 2 diabetic patients poorly controlled with sub-maximal glimepiride. | 2009 Oct |
1 |
| 188 |
19774848 | Improved diabetic control during oral sulfonylurea treatment in two children with permanent neonatal diabetes mellitus. | 2009 Jul |
1 |
| 189 |
19885647 | Cellular glucose transport and glucotransporter 4 expression as a therapeutic target: clinical and experimental studies. | 2009 Nov-Dec |
1 |
| 190 |
19950754 | [Role of standard test meal in initiation of insulin therapy in type 2 diabetes]. | 2009 Sep-Oct |
2 |
| 191 |
23105828 | Effects of insulin, glimepiride and combination therapy of insulin and metformin on blood sugar and lipid profile of NIDDM patients. | 2009 Apr |
3 |
| 192 |
18025408 | Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. | 2008 Feb |
1 |
| 193 |
18156614 | The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. | 2008 Jan |
1 |
| 194 |
18191448 | Impact of mitochondrial calcium on the coupling of metabolism to insulin secretion in the pancreatic beta-cell. | 2008 Jul |
1 |
| 195 |
18215172 | Hypoglycaemia in Type 2 diabetes. | 2008 Mar |
1 |
| 196 |
18227474 | Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted? | 2008 Feb |
1 |
| 197 |
18246324 | Too much of a good thing: why it is bad to stimulate the beta cell to secrete insulin. | 2008 Apr |
1 |
| 198 |
18378631 | Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. | 2008 Apr 2 |
1 |
| 199 |
18397831 | IL-12 serum levels in patients with type 2 diabetes treated with sulphonylureas. | 2008 Jun |
2 |
| 200 |
18397986 | Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus. | 2008 Jun |
2 |